Drugs / YOLT-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06458010 | May 2024 → Jan 2026 overdue | familial hypercholesterolemia | RenJi Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT06461702 | Apr 2024 → Aug 2025 | familial hypercholesterolemia | The First Affiliated Hospital of Bengbu Medical University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-07-14 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Regulatory 速递！碱基编辑疗法YOLT-101临床试验获批，用于治疗家族性高胆固醇血症 salubris.com ↗
近日，信立泰宣布，其引进的创新基因编辑药物YOLT-101注射液（下称“YOLT-101”）已获得国家药品监督管理局的临床试验默示许可。 |
| 2025-04-17 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Regulatory 信立泰PCSK9碱基编辑药物YOLT-101临床试验申请获受理 salubris.com ↗
今日，信立泰宣布，其从尧唐（上海）生物科技有限公司（下称“尧唐生物”）引进的创新基因编辑药物YOLT-101注射液（下称“YOLT-101”）临床试验申请已获国家药品监督管理局（NMPA）正式受理。 |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-07-14 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 速递！碱基编辑疗法YOLT-101临床试验获批，用于治疗家族性高胆固醇血症 salubris.com ↗ |
| 2025-04-17 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 信立泰PCSK9碱基编辑药物YOLT-101临床试验申请获受理 salubris.com ↗ |
| 2024-08-27 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 信立泰获碱基编辑药物“YOLT-101”独家许可权 salubris.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YOLT-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06461702 ↗ |
| Route | Intravenous | “single intravenous dose of YOLT-101” PMID 41776075 ↗ Mar 2026 |